Roche halts lung drug combo test

Share this content:

Roche has canned its exploratory combination of onartuzumab and Tarceva among previously treated, advanced non-small cell lung cancer patients with MET-positive tumors.

The company said in a statement Monday that it halted Phase-III studies “due to a lack of clinically meaningful efficacy.”

The company also said the findings have prompted a review of its other onartuzumab clinical trials.

Monday's news follows a Reuters story that indicates that although Roche and Novartis have been buddying up of late that a merger is not in the works.

Share this content:
Scroll down to see the next article